← Back to all trials
Recruiting
NCT06339658
ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Conditions: Breast Cancer, Axillary Metastases
Sex: Female
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 43
Sponsor: Hospital Universitari de Bellvitge
Location: Hospital de Bellvitge L'Hospitalet de Llobregat Barcelona
Summary
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Eligibility Criteria
Inclusion Criteria:
* Breast cancer cN+ patients who undergo neadjuvant treatment.
Exclusion Criteria:
* Patients in whom there is a contraindication for the use of ICG.
* Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.
Source: ClinicalTrials.gov (NCT06339658). StuddyBuddy aggregates publicly available trial information.
